Cardio Diagnostics Expands AI-Driven Genetic-Epigenetic Platform for Precision Heart Disease Prevention
CDIO•Cardio Diagnostics is scaling its AI-driven genetic-epigenetic platform to expand precision cardiovascular testing capabilities, targeting earlier prevention of life-threatening events. The company’s strategy hinges on integrating molecular insights and scalable testing to make personalized cardiovascular prevention more accessible.
1. Strategic Vision for Precision Cardiovascular Care
Cardio Diagnostics is leveraging its proprietary AI-powered Core Technology engine to combine genetic and epigenetic data, aiming to shift cardiovascular care toward prediction and prevention before critical cardiac events occur. This approach underscores the company’s goal to use individualized molecular profiles to guide early interventions.
2. Platform and Testing Expansion
The company is advancing its testing capabilities to increase throughput and accessibility, positioning its assays for broader clinical adoption. By scaling molecular analysis and improving accessibility, Cardio Diagnostics seeks to capture a growing share of the precision medicine market focused on cardiovascular disease prevention.
